# Prostacyclin pathway drugs

Drug · id `cardio:prostacyclin-pathway-drugs` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Prostacyclin; Prostacyclin Receptor Agonist; Prostacyclin Receptor Agonists; Prostacyclin mimetic; Prostacycline Vasodilator

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Prostacyclin pathway drugs are medicines that act like prostacyclin, a natural substance, or that act on its receptor. MeSH describes epoprostenol (prostacyclin) as a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation, and notes that its sodium salt has been used to treat primary pulmonary hypertension. The US label of Uptravi (selexipag) calls it a prostacyclin receptor agonist, and the US label of Remodulin (treprostinil) calls it a prostacyclin mimetic, each indicated for pulmonary arterial hypertension. This is the class page.

## Technical summary

Class page. MeSH has no descriptor for the class; the nearest is D011464 (Epoprostenol, lastUpdated 2018-03-01), a drug descriptor whose entry terms include Prostacyclin, so it is a broad match. Its scope note describes a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. RxClass lists the established pharmacologic class on US drug labels Prostacyclin Receptor Agonist for selexipag and, spelled Prostacycline Vasodilator, for treprostinil and epoprostenol (read 2026-11-18); the aliases keep those spellings. The labels read are Uptravi (NDA207947, NDA214275; effective 2026-05-28) and Remodulin (NDA021272; effective 2026-07-02). RxClass gives these medicines two different established pharmacologic class names, so the class page groups them by label wording. No trial result, dose or instruction is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- The Uptravi and Remodulin labels list pulmonary arterial hypertension as the indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Pulmonary arterial hypertension is one type of pulmonary hypertension: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Has subtype: Selexipag (`cardio:selexipag`)
- Has subtype: Treprostinil (`cardio:treprostinil`)

## Provenance

Content hash: e14aebe12d533e167818f037bbc9c36c7ed5607d8b621b181246d602d72ce3b0
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
